Continuing the Story: AstraZeneca and Mindpeak GmbH present new real-world results on AI-assisted HER2 scoring at ASCO 2025Following our oral presentation last Friday on the AI-assisted training for HER2 IHC interpretation, we are proud to share insights on the Monday’s poster session that took place at this year American Society of Clinical Oncology (ASCO) Annual Meeting.This time, it’s about  real-world diagnostics. In collaboration with six academic centers across the globe, we evaluated whether AI can truly enhance accuracy and consistency in daily pathology practice.And the answer is clear:AI support boosted diagnostic agreement  among pathologists to 86.4% for HER2-low and by 15% to 80.6% for HER2-ultralow - a major leap in consensus for some of the most challenging scoring decisions.Misclassification of HER2-null cases dropped by 64.5%, meaning more patients who may benefit from novel therapies like Enhertu can now be correctly identified.Accuracy rose across the board, especially in the critical 0 vs. 1+ distinction - an area long known for variability and clinical impact.Together, the oral and poster presentations offer a comprehensive view of how AI can support reproducible, high-quality HER2 assessment at scale - from training to clinical practice.As the clinical importance of HER2-low and ultralow scoring continues to grow, our findings provide strong evidence that AI can play a pivotal role in expanding access to targeted therapies like Enhertu - by enabling greater diagnostic precision.